261 related articles for article (PubMed ID: 28854728)
1. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Abbara A; Clarke S; Islam R; Prague JK; Comninos AN; Narayanaswamy S; Papadopoulou D; Roberts R; Izzi-Engbeaya C; Ratnasabapathy R; Nesbitt A; Vimalesvaran S; Salim R; Lavery SA; Bloom SR; Huson L; Trew GH; Dhillo WS
Hum Reprod; 2017 Sep; 32(9):1915-1924. PubMed ID: 28854728
[TBL] [Abstract][Full Text] [Related]
2. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.
Abbara A; Jayasena CN; Christopoulos G; Narayanaswamy S; Izzi-Engbeaya C; Nijher GM; Comninos AN; Peters D; Buckley A; Ratnasabapathy R; Prague JK; Salim R; Lavery SA; Bloom SR; Szigeti M; Ashby DA; Trew GH; Dhillo WS
J Clin Endocrinol Metab; 2015 Sep; 100(9):3322-31. PubMed ID: 26192876
[TBL] [Abstract][Full Text] [Related]
4. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
5. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
6. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
7. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
[TBL] [Abstract][Full Text] [Related]
8. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study.
Qiu Q; Huang J; Li Y; Chen X; Lin H; Li L; Yang D; Wang W; Zhang Q
Hum Reprod; 2020 Jun; 35(6):1411-1420. PubMed ID: 32383771
[TBL] [Abstract][Full Text] [Related]
9. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
10. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
11. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
Abbara A; Islam R; Clarke SA; Jeffers L; Christopoulos G; Comninos AN; Salim R; Lavery SA; Vuong TNL; Humaidan P; Kelsey TW; Trew GH; Dhillo WS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):920-927. PubMed ID: 29446481
[TBL] [Abstract][Full Text] [Related]
12. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
13. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
Zheng X; Guo W; Zeng L; Zheng D; Yang S; Xu Y; Wang L; Wang R; Mol BW; Li R; Qiao J
Hum Reprod; 2022 Jan; 37(2):242-253. PubMed ID: 34849920
[TBL] [Abstract][Full Text] [Related]
14. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
16. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
[TBL] [Abstract][Full Text] [Related]
18. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
19. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
20. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
